undamentalytics Newsletter
Sign in

Kyntra BIO, Inc. income statement

In fiscal 2025, Kyntra BIO, Inc. reported revenue of $6.4m, down 78.3% on the year before, operating income of −$45.9m (a -712.7% margin) and net income of $183m, or $45.37 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue102138181183131213257176235141473065
Cost of revenue——————19132041614
Gross profit——————255167222120431460
Research and development86151214187197236209253387297266962423
Selling, general and administrative————526413510612412586492828
General and administrative24374446——————————
Operating income−8−50−78−50−117−87−89−192−289−301−323−150−46−50
Interest expense11111111101132118899
Income before tax−15−60−86−58−121−86−77−189−291−295−323−153−58−31
Income tax000−0000000−0−0−0−0
Net income−15−60−86−58−121−86−77−189−290−294−284−48183183
Diluted EPS−$28.25−$79.25−$1.42−$0.93−$1.66−$1.03−$0.89−$2.11−$3.14−$3.14−$2.92−$11.89$45.37$45.27
Diluted shares (average)——2m3m3m3m3m4m4m4m4m4m4m4m
EBITDA−3−46−72−44−111−80−78−180−278−291−313−148−45−50

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: KYNB vs OCGNKYNB vs TRDABOLT vs KYNB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kyntra BIO, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kyntra BIO, Inc.